| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus | 67 | 2024 | 5891 | 5.640 |
Why?
|
| Endocrinology | 25 | 2023 | 444 | 4.520 |
Why?
|
| Patient-Centered Care | 23 | 2020 | 1458 | 3.400 |
Why?
|
| Diabetes Mellitus, Type 1 | 20 | 2024 | 3446 | 2.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 41 | 2023 | 12240 | 1.950 |
Why?
|
| Blood Glucose | 24 | 2022 | 6424 | 1.710 |
Why?
|
| Primary Health Care | 18 | 2023 | 4736 | 1.640 |
Why?
|
| Hypoglycemia | 7 | 2022 | 896 | 1.430 |
Why?
|
| Diabetes Complications | 8 | 2018 | 1316 | 1.340 |
Why?
|
| Hyperglycemia | 12 | 2024 | 1393 | 1.320 |
Why?
|
| Self Care | 10 | 2018 | 800 | 1.190 |
Why?
|
| Family Practice | 3 | 2016 | 508 | 1.190 |
Why?
|
| Hypoglycemic Agents | 18 | 2022 | 3110 | 1.180 |
Why?
|
| Pennsylvania | 13 | 2016 | 614 | 1.090 |
Why?
|
| Case Management | 4 | 2013 | 277 | 1.080 |
Why?
|
| Insulin | 18 | 2021 | 6599 | 1.070 |
Why?
|
| Blood Glucose Self-Monitoring | 10 | 2022 | 475 | 0.940 |
Why?
|
| Podiatry | 2 | 2014 | 28 | 0.820 |
Why?
|
| Standard of Care | 20 | 2023 | 567 | 0.800 |
Why?
|
| Education, Continuing | 1 | 2023 | 115 | 0.790 |
Why?
|
| Glucagon | 3 | 2021 | 533 | 0.780 |
Why?
|
| Reference Standards | 19 | 2023 | 1013 | 0.750 |
Why?
|
| Fellowships and Scholarships | 2 | 2020 | 1135 | 0.740 |
Why?
|
| Professional Role | 2 | 2014 | 313 | 0.710 |
Why?
|
| Diabetic Ketoacidosis | 5 | 2024 | 253 | 0.700 |
Why?
|
| Biomedical Technology | 2 | 2018 | 210 | 0.670 |
Why?
|
| Practice Management, Medical | 2 | 2018 | 191 | 0.650 |
Why?
|
| Attitude of Health Personnel | 6 | 2016 | 3925 | 0.650 |
Why?
|
| Competitive Bidding | 1 | 2019 | 16 | 0.640 |
Why?
|
| Reagent Strips | 1 | 2019 | 40 | 0.630 |
Why?
|
| Disease Management | 6 | 2019 | 2535 | 0.610 |
Why?
|
| Health Care Costs | 7 | 2024 | 3242 | 0.610 |
Why?
|
| Health Educators | 1 | 2018 | 19 | 0.610 |
Why?
|
| Organizational Innovation | 7 | 2018 | 541 | 0.600 |
Why?
|
| Blood Chemical Analysis | 1 | 2019 | 433 | 0.550 |
Why?
|
| Patient Care Team | 7 | 2021 | 2517 | 0.550 |
Why?
|
| Quality Improvement | 6 | 2023 | 3853 | 0.550 |
Why?
|
| Cooperative Behavior | 3 | 2016 | 1509 | 0.550 |
Why?
|
| Motivation | 7 | 2017 | 2018 | 0.530 |
Why?
|
| Emergency Medical Services | 2 | 2018 | 1938 | 0.530 |
Why?
|
| Internet | 4 | 2015 | 3106 | 0.530 |
Why?
|
| Humans | 147 | 2024 | 765968 | 0.520 |
Why?
|
| Models, Organizational | 7 | 2018 | 547 | 0.510 |
Why?
|
| Patient Education as Topic | 7 | 2017 | 2334 | 0.500 |
Why?
|
| Models, Economic | 2 | 2016 | 716 | 0.490 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2019 | 746 | 0.490 |
Why?
|
| Health Care Reform | 4 | 2013 | 1259 | 0.480 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 7425 | 0.450 |
Why?
|
| Comprehensive Health Care | 1 | 2015 | 123 | 0.440 |
Why?
|
| Career Choice | 1 | 2020 | 769 | 0.440 |
Why?
|
| Quality Assurance, Health Care | 4 | 2014 | 2172 | 0.440 |
Why?
|
| Telemedicine | 6 | 2021 | 3105 | 0.440 |
Why?
|
| Nurses | 3 | 2014 | 2505 | 0.430 |
Why?
|
| Societies, Medical | 19 | 2023 | 3956 | 0.420 |
Why?
|
| Insulin Infusion Systems | 2 | 2005 | 220 | 0.410 |
Why?
|
| Health Plan Implementation | 2 | 2016 | 338 | 0.400 |
Why?
|
| United States | 29 | 2024 | 72903 | 0.390 |
Why?
|
| Insulin-Secreting Cells | 1 | 2019 | 898 | 0.390 |
Why?
|
| Self-Help Groups | 1 | 2013 | 193 | 0.380 |
Why?
|
| Physicians | 3 | 2020 | 4588 | 0.380 |
Why?
|
| Health Priorities | 1 | 2014 | 382 | 0.380 |
Why?
|
| Burnout, Professional | 1 | 2020 | 711 | 0.370 |
Why?
|
| Drug Costs | 1 | 2019 | 1193 | 0.370 |
Why?
|
| Patient Protection and Affordable Care Act | 3 | 2016 | 1188 | 0.360 |
Why?
|
| Health Services | 2 | 2024 | 756 | 0.350 |
Why?
|
| Physician Assistants | 1 | 2013 | 190 | 0.350 |
Why?
|
| Health Care Surveys | 2 | 2015 | 2424 | 0.350 |
Why?
|
| Quality of Health Care | 8 | 2018 | 4300 | 0.340 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 2780 | 0.320 |
Why?
|
| Monitoring, Ambulatory | 3 | 2019 | 357 | 0.320 |
Why?
|
| Organizational Culture | 1 | 2013 | 514 | 0.320 |
Why?
|
| Chronic Disease | 7 | 2016 | 9347 | 0.310 |
Why?
|
| Models, Psychological | 1 | 2013 | 824 | 0.310 |
Why?
|
| Directive Counseling | 1 | 2010 | 171 | 0.310 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 8041 | 0.280 |
Why?
|
| Interviews as Topic | 3 | 2016 | 2739 | 0.280 |
Why?
|
| Cholesterol, LDL | 3 | 2012 | 2393 | 0.270 |
Why?
|
| Interview, Psychological | 1 | 2010 | 812 | 0.270 |
Why?
|
| Perioperative Care | 2 | 2012 | 1055 | 0.270 |
Why?
|
| Software | 3 | 2019 | 4462 | 0.270 |
Why?
|
| Diabetic Foot | 1 | 2011 | 384 | 0.270 |
Why?
|
| Registries | 3 | 2009 | 8297 | 0.260 |
Why?
|
| Medical Informatics | 1 | 2013 | 745 | 0.260 |
Why?
|
| Length of Stay | 4 | 2016 | 6485 | 0.260 |
Why?
|
| Ophthalmology | 2 | 2010 | 561 | 0.250 |
Why?
|
| United States Agency for Healthcare Research and Quality | 2 | 2016 | 85 | 0.250 |
Why?
|
| Autoantibodies | 2 | 2024 | 2113 | 0.250 |
Why?
|
| Research Design | 2 | 2019 | 6209 | 0.240 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 936 | 0.240 |
Why?
|
| Quality Indicators, Health Care | 2 | 2017 | 1806 | 0.240 |
Why?
|
| Medicine | 1 | 2013 | 942 | 0.240 |
Why?
|
| Inpatients | 3 | 2012 | 2564 | 0.240 |
Why?
|
| Internship and Residency | 2 | 2016 | 5946 | 0.240 |
Why?
|
| Patient Satisfaction | 3 | 2013 | 3475 | 0.230 |
Why?
|
| Cardiovascular Diseases | 3 | 2023 | 15652 | 0.230 |
Why?
|
| Mass Screening | 2 | 2009 | 5446 | 0.210 |
Why?
|
| Child Care | 1 | 2023 | 126 | 0.200 |
Why?
|
| Blood Pressure | 9 | 2015 | 8532 | 0.200 |
Why?
|
| Medication Adherence | 2 | 2014 | 2192 | 0.200 |
Why?
|
| Administrative Personnel | 2 | 2014 | 186 | 0.200 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3100 | 0.200 |
Why?
|
| Patient Readmission | 1 | 2016 | 3286 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3223 | 0.200 |
Why?
|
| Referral and Consultation | 4 | 2021 | 3615 | 0.200 |
Why?
|
| Health Promotion | 1 | 2014 | 2208 | 0.200 |
Why?
|
| Hyperoxia | 2 | 2015 | 260 | 0.190 |
Why?
|
| Female | 41 | 2023 | 396112 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 5 | 2019 | 5526 | 0.180 |
Why?
|
| Pandemics | 1 | 2020 | 8703 | 0.170 |
Why?
|
| Prediabetic State | 2 | 2018 | 548 | 0.170 |
Why?
|
| Adult | 36 | 2024 | 223044 | 0.170 |
Why?
|
| Consensus | 6 | 2024 | 3202 | 0.160 |
Why?
|
| Male | 38 | 2021 | 363698 | 0.160 |
Why?
|
| Focus Groups | 4 | 2014 | 1459 | 0.160 |
Why?
|
| Ribavirin | 1 | 2001 | 395 | 0.160 |
Why?
|
| Delivery of Health Care | 5 | 2021 | 5370 | 0.160 |
Why?
|
| Retinal Vessels | 3 | 2015 | 863 | 0.150 |
Why?
|
| Cyclic AMP | 4 | 1987 | 1467 | 0.150 |
Why?
|
| Vasodilation | 2 | 2013 | 970 | 0.150 |
Why?
|
| San Francisco | 1 | 2018 | 166 | 0.150 |
Why?
|
| Health Personnel | 3 | 2023 | 3390 | 0.150 |
Why?
|
| Pharmacists | 1 | 2021 | 260 | 0.150 |
Why?
|
| Eating | 1 | 2005 | 1540 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2011 | 3278 | 0.150 |
Why?
|
| Needs Assessment | 2 | 2017 | 1138 | 0.150 |
Why?
|
| Middle Aged | 31 | 2020 | 223009 | 0.150 |
Why?
|
| Continuity of Patient Care | 2 | 2016 | 1078 | 0.150 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (GTP) | 2 | 1996 | 38 | 0.140 |
Why?
|
| Diabetic Retinopathy | 3 | 2013 | 1299 | 0.140 |
Why?
|
| Biotechnology | 1 | 2019 | 284 | 0.140 |
Why?
|
| Comorbidity | 4 | 2023 | 10563 | 0.140 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2023 | 712 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3251 | 0.140 |
Why?
|
| Endpoint Determination | 1 | 2019 | 591 | 0.130 |
Why?
|
| Vasoconstriction | 2 | 2012 | 594 | 0.130 |
Why?
|
| Retinal Diseases | 1 | 2023 | 709 | 0.130 |
Why?
|
| Interferon-alpha | 1 | 2001 | 910 | 0.130 |
Why?
|
| Privacy | 1 | 2018 | 233 | 0.130 |
Why?
|
| Risk Factors | 8 | 2021 | 74840 | 0.130 |
Why?
|
| Nurse's Role | 3 | 2013 | 187 | 0.130 |
Why?
|
| Critical Care | 3 | 2020 | 2712 | 0.130 |
Why?
|
| Computers | 1 | 2018 | 588 | 0.130 |
Why?
|
| Hypertension | 1 | 2016 | 8626 | 0.130 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 1996 | 89 | 0.120 |
Why?
|
| Liver Glycogen | 2 | 1986 | 36 | 0.120 |
Why?
|
| Wounds and Injuries | 2 | 2007 | 2511 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2017 | 4058 | 0.120 |
Why?
|
| Health Services Accessibility | 4 | 2019 | 5508 | 0.120 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 390 | 0.120 |
Why?
|
| Tomography, Optical Coherence | 1 | 2008 | 2932 | 0.120 |
Why?
|
| Treatment Outcome | 11 | 2019 | 65188 | 0.120 |
Why?
|
| Coronary Artery Bypass | 1 | 2004 | 2186 | 0.120 |
Why?
|
| Aged | 21 | 2024 | 171117 | 0.120 |
Why?
|
| Confidentiality | 1 | 2018 | 607 | 0.110 |
Why?
|
| Nutrition Policy | 1 | 2018 | 467 | 0.110 |
Why?
|
| Hyperglycemic Hyperosmolar Nonketotic Coma | 2 | 2024 | 30 | 0.110 |
Why?
|
| Obesity | 3 | 2023 | 13076 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2018 | 811 | 0.110 |
Why?
|
| Telecommunications | 1 | 2014 | 79 | 0.110 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 939 | 0.110 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1996 | 434 | 0.110 |
Why?
|
| Health Behavior | 3 | 2023 | 2650 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 1123 | 0.100 |
Why?
|
| Nurse-Patient Relations | 1 | 2013 | 102 | 0.100 |
Why?
|
| Practice Management | 1 | 2013 | 37 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2001 | 1032 | 0.100 |
Why?
|
| Diabetic Angiopathies | 3 | 2015 | 805 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2018 | 1574 | 0.100 |
Why?
|
| Adaptation, Psychological | 2 | 2013 | 2660 | 0.100 |
Why?
|
| Medicare | 2 | 2024 | 6823 | 0.090 |
Why?
|
| Curriculum | 2 | 2016 | 3782 | 0.090 |
Why?
|
| Lipoproteins, LDL | 2 | 2013 | 643 | 0.090 |
Why?
|
| Calcium | 4 | 2006 | 5767 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 1394 | 0.090 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2013 | 228 | 0.090 |
Why?
|
| Nurse Practitioners | 1 | 2014 | 272 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2019 | 24282 | 0.090 |
Why?
|
| Perioperative Period | 1 | 2012 | 251 | 0.090 |
Why?
|
| Withholding Treatment | 1 | 2014 | 621 | 0.090 |
Why?
|
| Coronary Disease | 3 | 2015 | 5912 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 1672 | 0.090 |
Why?
|
| Young Adult | 7 | 2021 | 59889 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 2229 | 0.080 |
Why?
|
| Nursing Homes | 1 | 2017 | 1084 | 0.080 |
Why?
|
| Injections, Subcutaneous | 1 | 2011 | 682 | 0.080 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 2 | 1986 | 99 | 0.080 |
Why?
|
| Education, Nursing, Continuing | 1 | 2009 | 68 | 0.080 |
Why?
|
| Photic Stimulation | 2 | 2013 | 1993 | 0.080 |
Why?
|
| Electrical Equipment and Supplies | 1 | 2009 | 28 | 0.080 |
Why?
|
| Cost of Illness | 2 | 2024 | 1950 | 0.080 |
Why?
|
| Adolescent | 8 | 2023 | 88835 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 2310 | 0.080 |
Why?
|
| Kidney Transplantation | 1 | 2003 | 4270 | 0.080 |
Why?
|
| Health Maintenance Organizations | 2 | 2002 | 656 | 0.080 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 953 | 0.080 |
Why?
|
| Medicaid | 2 | 2014 | 2833 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2001 | 3050 | 0.080 |
Why?
|
| Glasgow Coma Scale | 2 | 2007 | 575 | 0.080 |
Why?
|
| Diabetes, Gestational | 1 | 2018 | 1263 | 0.070 |
Why?
|
| Mentors | 1 | 2014 | 671 | 0.070 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 622 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2016 | 15747 | 0.070 |
Why?
|
| Islets of Langerhans | 2 | 2024 | 1349 | 0.070 |
Why?
|
| Self Efficacy | 2 | 2009 | 642 | 0.070 |
Why?
|
| Lactates | 2 | 1986 | 398 | 0.070 |
Why?
|
| Qualitative Research | 3 | 2014 | 3139 | 0.070 |
Why?
|
| Preoperative Care | 2 | 2009 | 2267 | 0.070 |
Why?
|
| Quality of Life | 4 | 2019 | 13462 | 0.070 |
Why?
|
| Overweight | 1 | 2018 | 2444 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 10729 | 0.070 |
Why?
|
| Inservice Training | 1 | 2009 | 375 | 0.070 |
Why?
|
| Urban Population | 1 | 2015 | 2040 | 0.070 |
Why?
|
| Sciatic Nerve | 1 | 1990 | 628 | 0.070 |
Why?
|
| Injury Severity Score | 2 | 2007 | 1050 | 0.070 |
Why?
|
| New York City | 1 | 2009 | 733 | 0.070 |
Why?
|
| Postprandial Period | 2 | 2006 | 319 | 0.070 |
Why?
|
| Sebum | 1 | 2006 | 17 | 0.070 |
Why?
|
| Sebaceous Glands | 1 | 2006 | 42 | 0.070 |
Why?
|
| Oxaloacetates | 1 | 1985 | 5 | 0.060 |
Why?
|
| Quinolinic Acids | 1 | 1985 | 15 | 0.060 |
Why?
|
| Theophylline | 1 | 1986 | 132 | 0.060 |
Why?
|
| Nursing Staff, Hospital | 1 | 2009 | 350 | 0.060 |
Why?
|
| Pressure Ulcer | 1 | 2007 | 155 | 0.060 |
Why?
|
| Drug Therapy, Combination | 3 | 2007 | 6309 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 1990 | 1202 | 0.060 |
Why?
|
| Fenofibrate | 1 | 2006 | 87 | 0.060 |
Why?
|
| Decision Making | 2 | 2018 | 3965 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2012 | 1187 | 0.060 |
Why?
|
| Pyruvates | 1 | 1985 | 84 | 0.060 |
Why?
|
| Health Services Research | 1 | 2013 | 1808 | 0.060 |
Why?
|
| Faculty, Medical | 1 | 2014 | 1219 | 0.060 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 1985 | 50 | 0.060 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 1986 | 213 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2017 | 10070 | 0.060 |
Why?
|
| Hyperlipidemias | 2 | 2007 | 770 | 0.060 |
Why?
|
| PPAR alpha | 1 | 2006 | 175 | 0.060 |
Why?
|
| Enteral Nutrition | 1 | 2011 | 803 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2006 | 375 | 0.060 |
Why?
|
| Gluconeogenesis | 1 | 1985 | 183 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2021 | 81514 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 830 | 0.060 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2005 | 355 | 0.060 |
Why?
|
| Database Management Systems | 1 | 2005 | 263 | 0.060 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1990 | 1118 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 2418 | 0.060 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2009 | 934 | 0.060 |
Why?
|
| Reference Values | 2 | 2008 | 4908 | 0.050 |
Why?
|
| Hemostasis | 1 | 2006 | 467 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2012 | 1142 | 0.050 |
Why?
|
| Glucose | 3 | 2006 | 4335 | 0.050 |
Why?
|
| Glycemic Index | 1 | 2006 | 400 | 0.050 |
Why?
|
| Lipolysis | 1 | 1985 | 211 | 0.050 |
Why?
|
| Counseling | 1 | 2011 | 1551 | 0.050 |
Why?
|
| Medical Records | 1 | 2009 | 1409 | 0.050 |
Why?
|
| Morbidity | 1 | 2009 | 1749 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2006 | 1180 | 0.050 |
Why?
|
| PPAR gamma | 1 | 2006 | 483 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2008 | 4015 | 0.050 |
Why?
|
| Cataract | 1 | 2009 | 837 | 0.050 |
Why?
|
| Child Day Care Centers | 1 | 2023 | 122 | 0.050 |
Why?
|
| Clinical Competence | 2 | 2016 | 4863 | 0.050 |
Why?
|
| International Cooperation | 1 | 2009 | 1432 | 0.050 |
Why?
|
| Documentation | 1 | 2009 | 916 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2015 | 8733 | 0.050 |
Why?
|
| Rats, Inbred Strains | 3 | 1990 | 2077 | 0.050 |
Why?
|
| Social Support | 1 | 2012 | 2192 | 0.050 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 608 | 0.050 |
Why?
|
| Aging | 1 | 2020 | 8731 | 0.050 |
Why?
|
| 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 3 | 1986 | 7 | 0.050 |
Why?
|
| Epinephrine | 1 | 1985 | 783 | 0.050 |
Why?
|
| Dietary Carbohydrates | 1 | 2006 | 894 | 0.050 |
Why?
|
| Rats | 8 | 2000 | 23707 | 0.050 |
Why?
|
| Urinary Tract Infections | 1 | 2007 | 805 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 15398 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2000 | 19 | 0.040 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2006 | 1499 | 0.040 |
Why?
|
| Liver | 4 | 1996 | 7562 | 0.040 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 59489 | 0.040 |
Why?
|
| Regional Blood Flow | 2 | 2013 | 1478 | 0.040 |
Why?
|
| Glaucoma | 1 | 2009 | 1194 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 4850 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2005 | 2108 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 10383 | 0.040 |
Why?
|
| Incidence | 1 | 2016 | 21480 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2009 | 1941 | 0.040 |
Why?
|
| Health Status | 2 | 2009 | 4080 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3685 | 0.040 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2004 | 1727 | 0.040 |
Why?
|
| Diabetic Nephropathies | 1 | 2004 | 969 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 1996 | 3586 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2004 | 1470 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2007 | 2247 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2003 | 2652 | 0.040 |
Why?
|
| Mid-Atlantic Region | 1 | 2016 | 24 | 0.030 |
Why?
|
| Culture Media | 1 | 2019 | 890 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2008 | 5302 | 0.030 |
Why?
|
| Preconception Care | 1 | 2018 | 142 | 0.030 |
Why?
|
| Transferases | 1 | 1996 | 71 | 0.030 |
Why?
|
| Farnesyltranstransferase | 1 | 1996 | 70 | 0.030 |
Why?
|
| Arteriosclerosis | 1 | 2000 | 1053 | 0.030 |
Why?
|
| Chromones | 1 | 1996 | 148 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2007 | 2709 | 0.030 |
Why?
|
| Europe | 1 | 2022 | 3423 | 0.030 |
Why?
|
| Body Mass Index | 3 | 2009 | 13039 | 0.030 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 2 | 1986 | 72 | 0.030 |
Why?
|
| Pneumonia | 1 | 2007 | 2157 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2007 | 1946 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2015 | 22223 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 490 | 0.030 |
Why?
|
| Arterioles | 1 | 2015 | 251 | 0.030 |
Why?
|
| Child | 5 | 2023 | 80564 | 0.030 |
Why?
|
| Kinetics | 3 | 1987 | 6274 | 0.030 |
Why?
|
| Pyridines | 1 | 1985 | 2888 | 0.030 |
Why?
|
| Sepsis | 1 | 2007 | 2606 | 0.030 |
Why?
|
| Survival Rate | 1 | 2007 | 12795 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 1985 | 3312 | 0.030 |
Why?
|
| Morpholines | 1 | 1996 | 577 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2018 | 906 | 0.030 |
Why?
|
| Health Services Needs and Demand | 2 | 2012 | 1406 | 0.030 |
Why?
|
| Pluripotent Stem Cells | 1 | 2019 | 807 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2000 | 1792 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2004 | 2067 | 0.020 |
Why?
|
| Goals | 1 | 2017 | 719 | 0.020 |
Why?
|
| Mitral Valve | 1 | 2000 | 1476 | 0.020 |
Why?
|
| Time Factors | 3 | 2019 | 40065 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 39193 | 0.020 |
Why?
|
| Calcinosis | 1 | 2000 | 1479 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1996 | 1167 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 6493 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2024 | 2387 | 0.020 |
Why?
|
| Heart Rate | 2 | 2013 | 4204 | 0.020 |
Why?
|
| Trifluoperazine | 1 | 1990 | 40 | 0.020 |
Why?
|
| Polymyxin B | 1 | 1990 | 43 | 0.020 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1990 | 56 | 0.020 |
Why?
|
| Asthma | 1 | 2010 | 6270 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2019 | 1602 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 1987 | 5696 | 0.020 |
Why?
|
| Lactic Acid | 2 | 1986 | 1137 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 1429 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2003 | 4499 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 1789 | 0.020 |
Why?
|
| Diglycerides | 1 | 1990 | 174 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 20124 | 0.020 |
Why?
|
| Chromatography, Gel | 1 | 1990 | 629 | 0.020 |
Why?
|
| Blood Flow Velocity | 2 | 2006 | 1381 | 0.020 |
Why?
|
| Nursing Education Research | 1 | 2009 | 11 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2009 | 63 | 0.020 |
Why?
|
| Hospitals | 1 | 2023 | 3888 | 0.020 |
Why?
|
| Models, Nursing | 1 | 2009 | 46 | 0.020 |
Why?
|
| Phosphatidylserines | 1 | 1990 | 184 | 0.020 |
Why?
|
| Depression | 1 | 2009 | 8237 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 2015 | 1602 | 0.020 |
Why?
|
| Isoquinolines | 1 | 1990 | 350 | 0.020 |
Why?
|
| Pregnancy | 2 | 2023 | 30260 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2015 | 1870 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2017 | 2499 | 0.020 |
Why?
|
| Transfection | 1 | 1996 | 5743 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1996 | 1761 | 0.020 |
Why?
|
| Societies | 1 | 2008 | 106 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2022 | 54802 | 0.020 |
Why?
|
| Writing | 1 | 2009 | 199 | 0.020 |
Why?
|
| Hospitalization | 1 | 2007 | 10808 | 0.020 |
Why?
|
| Disease Progression | 1 | 2024 | 13632 | 0.020 |
Why?
|
| Total Quality Management | 1 | 2008 | 264 | 0.020 |
Why?
|
| Health Surveys | 2 | 2010 | 4056 | 0.020 |
Why?
|
| Phospholipids | 1 | 1990 | 776 | 0.020 |
Why?
|
| Phenylisopropyladenosine | 1 | 1986 | 14 | 0.020 |
Why?
|
| Gemfibrozil | 1 | 2006 | 30 | 0.020 |
Why?
|
| Models, Educational | 1 | 2009 | 376 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 1996 | 2878 | 0.020 |
Why?
|
| Concanavalin A | 1 | 1986 | 191 | 0.020 |
Why?
|
| Skin | 1 | 2000 | 4489 | 0.020 |
Why?
|
| Aminoquinolines | 1 | 1986 | 102 | 0.020 |
Why?
|
| Quinolinic Acid | 1 | 1985 | 67 | 0.020 |
Why?
|
| Asparagine | 1 | 1985 | 120 | 0.020 |
Why?
|
| Oleic Acid | 1 | 1985 | 88 | 0.020 |
Why?
|
| Oleic Acids | 1 | 1985 | 70 | 0.020 |
Why?
|
| Phenylephrine | 1 | 1986 | 292 | 0.020 |
Why?
|
| Animals | 8 | 2000 | 168764 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 1996 | 3715 | 0.020 |
Why?
|
| Risk | 1 | 2017 | 9591 | 0.010 |
Why?
|
| Insulin, Long-Acting | 1 | 2005 | 59 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2006 | 858 | 0.010 |
Why?
|
| Isotretinoin | 1 | 2006 | 135 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2015 | 4184 | 0.010 |
Why?
|
| Pyruvic Acid | 1 | 1985 | 205 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1987 | 1430 | 0.010 |
Why?
|
| Vasopressins | 1 | 1986 | 359 | 0.010 |
Why?
|
| Lipogenesis | 1 | 2006 | 217 | 0.010 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 746 | 0.010 |
Why?
|
| Community Health Services | 1 | 2008 | 657 | 0.010 |
Why?
|
| Thiazolidinediones | 1 | 2006 | 459 | 0.010 |
Why?
|
| Cytosol | 1 | 1985 | 885 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2008 | 1441 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2006 | 1638 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2008 | 962 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1987 | 3051 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 3850 | 0.010 |
Why?
|
| Benchmarking | 1 | 2008 | 1052 | 0.010 |
Why?
|
| Lipids | 1 | 2012 | 3315 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1996 | 12768 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2023 | 42500 | 0.010 |
Why?
|
| Trauma Centers | 1 | 2006 | 952 | 0.010 |
Why?
|
| Sulfonamides | 1 | 1990 | 1984 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1996 | 18973 | 0.010 |
Why?
|
| Piperazines | 1 | 1990 | 2549 | 0.010 |
Why?
|
| Ligands | 1 | 2006 | 3273 | 0.010 |
Why?
|
| Diet | 1 | 2017 | 8086 | 0.010 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2000 | 353 | 0.010 |
Why?
|
| Point-of-Care Systems | 1 | 2008 | 1217 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 2002 | 674 | 0.010 |
Why?
|
| Metformin | 1 | 2005 | 904 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2000 | 1515 | 0.010 |
Why?
|
| Critical Illness | 1 | 2008 | 2744 | 0.010 |
Why?
|
| Protein Binding | 1 | 1987 | 9296 | 0.010 |
Why?
|
| Anxiety | 1 | 2009 | 4671 | 0.010 |
Why?
|
| Body Weight | 1 | 2005 | 4622 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 26318 | 0.010 |
Why?
|
| Prognosis | 2 | 2006 | 29922 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 14751 | 0.010 |
Why?
|
| Cholesterol | 1 | 2002 | 2898 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2000 | 1030 | 0.010 |
Why?
|
| Signal Transduction | 1 | 1996 | 23601 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 9443 | 0.010 |
Why?
|
| Logistic Models | 1 | 2006 | 13266 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2000 | 8102 | 0.000 |
Why?
|
| Socioeconomic Factors | 1 | 2002 | 7838 | 0.000 |
Why?
|
| Algorithms | 1 | 2008 | 14071 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 2000 | 15880 | 0.000 |
Why?
|